Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing

Objectives Children requiring cortisol replacement therapy are often prescribed hydrocortisone doses of 2.5 mg, but as this is commercially unavailable 10 mg tablets, with functional break lines, are split commonly in an attempt to deliver the correct dose. This study aimed to determine the dose variation obtained from quartered hydrocortisone tablets when different operators performed the splitting procedure and to ascertain whether better uniformity could be attained from mini-tablets as an alternative formulation. Methods Hydrocortisone 10 mg tablets were quartered by four different operators using a standard pill splitter. Hydrocortisone 2.5 mg mini-tablets (3 mm diameter) were formulated using a wet granulation method and manufactured using a high-speed rotary press simulator. The weight and content uniformity of the quartered tablets and mini-tablets were assessed according to pharmacopoeial standards. The physical strength and dissolution profiles of the mini-tablets were also determined. Results More than half of all quartered 10 mg tablets were outside of the ±10% of the stated US Pharmacopoeia hydrocortisone content (mean 2.34 mg, SD 0.36, coefficient of variation (CV) 15.18%) and more than 40% of the quartered tablets were outside the European Pharmacopoeia weight variation. Robust mini-tablets (tensile strengths of >4 MPa) were produced successfully. The mini-tablets passed the pharmacopoeial weight and content uniformity requirements (mean 2.54 mg, SD 0.04, CV 1.72%) and drug release criteria during in vitro dissolution testing. Conclusion This study confirmed that quartering 10 mg hydrocortisone tablets produces unacceptable dose variations and that it is feasible to produce 3 mm mini-tablets containing more accurate doses for paediatric patients.

[1]  I. Wong,et al.  When Do Children Convert from Liquid Antiretroviral to Solid Formulations? , 2005, Pharmacy World and Science.

[2]  J. Fell,et al.  The tensile strength of lactose tablets , 1968, The Journal of pharmacy and pharmacology.

[3]  G. Slegers,et al.  Statistical analysis of tablet breakability methods. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[4]  Anette Müllertz,et al.  Dissolution of Hydrocortisone in Human and Simulated Intestinal Fluids , 2000, Pharmaceutical Research.

[5]  J. Breitkreutz,et al.  Acceptability of Uncoated Mini-Tablets in Neonates--A Randomized Controlled Trial. , 2015, The Journal of pediatrics.

[6]  R L Carr,et al.  EVALUATING FLOW PROPERTIES OF SOLIDS , 1965 .

[7]  Matthew Roberts,et al.  Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets , 2012, Drug development and industrial pharmacy.

[8]  S. Eksborg,et al.  Dividing the Tablets for Children – Good or Bad? , 2016 .

[9]  Izabel Calland Ricarte Beserra,et al.  Health related quality of life of children and adolescents with congenital adrenal hyperplasia in Brazil , 2014, Health and Quality of Life Outcomes.

[10]  K. Kachrimanis,et al.  Flow rate of some pharmaceutical diluents through die-orifices relevant to mini-tableting. , 2005, International journal of pharmaceutics.

[11]  M. Dattani,et al.  Deconvolution analysis of 24‐h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy , 2011, Clinical endocrinology.

[12]  M. Mclean,et al.  Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency , 2007, Pediatrics.

[13]  G. Chrousos,et al.  Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  H W Frijlink,et al.  Breaking of scored tablets: a review. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  D. Gibb,et al.  Young HIV-Infected Children and Their Adult Caregivers Prefer Tablets to Syrup Antiretroviral Medications in Africa , 2012, PloS one.

[16]  Jörg Breitkreutz,et al.  Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. , 2013, The Journal of pediatrics.

[17]  J. Breitkreutz,et al.  Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study , 2012, Archives of Disease in Childhood.

[18]  P. Hindmarsh,et al.  Working memory performance is reduced in children with congenital adrenal hyperplasia , 2015, Hormones and Behavior.

[19]  J. Ford,et al.  Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence , 2013, BMC Pediatrics.

[20]  W. Miller Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  J. Ford,et al.  A systematic review of the use of dosage form manipulation to obtain required doses to inform use of manipulation in paediatric practice. , 2017, International journal of pharmaceutics.

[22]  George P Chrousos,et al.  Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  P. Murgatroyd,et al.  Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia , 2010, Clinical endocrinology.

[24]  H. Dörr,et al.  Obesity Among Children and Adolescents With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency , 2006, Pediatrics.

[25]  Canary Wharf,et al.  List of criteria for screening PIPs with regard to paediatric specific Quality issues and referring them to the PDCO FWG for discussion , 2013 .

[26]  Matthew Roberts,et al.  Production of extended release mini-tablets using directly compressible grades of HPMC , 2013, Drug development and industrial pharmacy.

[27]  D. Eckland,et al.  Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. , 2015, The Journal of clinical endocrinology and metabolism.

[28]  O. Decker,et al.  Influence of hydrocortisone dosage scheme on health‐related quality of life in patients with adrenal insufficiency , 2010, Clinical endocrinology.

[29]  K. Lackner,et al.  Alterations in Lipid and Carbohydrate Metabolism in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency , 2010, Hormone Research in Paediatrics.

[30]  P. Hindmarsh,et al.  Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2001, The Journal of endocrinology.

[31]  P. Hindmarsh,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. , 2001, The Journal of clinical endocrinology and metabolism.